Q1 2022 13F Holders as of 31 Mar 2022
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
50,580,036
-
Total 13F shares
-
23,950,478
-
Share change
-
-1,023,340
-
Total reported value
-
$353,046,504
-
Put/Call ratio
-
0%
-
Price per share
-
$14.74
-
Number of holders
-
84
-
Value change
-
-$11,733,222
-
Number of buys
-
38
-
Number of sells
-
46
Institutional Holders of KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV) as of Q1 2022
As of 31 Mar 2022,
KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV) was held by
84 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
23,950,478 shares.
The largest 10 holders included
RA CAPITAL MANAGEMENT, L.P., SUVRETTA CAPITAL MANAGEMENT, LLC, Deep Track Capital, LP, Frazier Life Sciences Management, L.P., BlackRock Inc., Vivo Capital, LLC, WELLINGTON MANAGEMENT GROUP LLP, FRANKLIN RESOURCES INC, VANGUARD GROUP INC, and STATE STREET CORP.
This page lists
84
institutional shareholders reporting positions in this security
for the Q1 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.